Catalog No.
YHK51601
Expression system
E. coli
Species
Homo sapiens (Human)
Protein length
Met1-Arg130
Predicted molecular weight
16.77 kDa
Nature
Recombinant
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
Q69YN4
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
KIAA1429, VIRMA, Protein virilizer homolog
Note
For research use only.
KIAA1429 mediates epithelial mesenchymal transition in sorafenib-resistant hepatocellular carcinoma through m6A methylation modification., PMID:36420693
IGF2BP3 is an essential N6-methyladenosine biotarget for suppressing ferroptosis in lung adenocarcinoma cells., PMID:36457846
The differences in biological behavior and gene expression characteristics between pure and mixed early gastric signet ring cell carcinomas., PMID:36529637
KIAA1429 promotes infantile hemangioma regression by facilitating the stemness of hemangioma endothelial cells., PMID:36572002
CCL3 secreted by hepatocytes promotes the metastasis of intrahepatic cholangiocarcinoma by VIRMA-mediated N6-methyladenosine (m6A) modification., PMID:36691046
Vir1p, the Yeast Homolog of Virilizer, is Required for mRNA m 6 A Methylation and Meiosis., PMID:36798303
Vir1p, the yeast homolog of virilizer, is required for mRNA m6A methylation and meiosis., PMID:36930734
VIRMA promotes nasopharyngeal carcinoma, tumorigenesis, and metastasis by upregulation of E2F7 in an m6A-dependent manner., PMID:37028765
KIAA1429-mediated m6A modification of CHST11 promotes progression of diffuse large B-cell lymphoma by regulating Hippo-YAP pathway., PMID:37076815
GPX8 deficiency-induced oxidative stress reprogrammed m6A epitranscriptome of oral cancer cells., PMID:37170591
Overexpression of VIRMA confers vulnerability to breast cancers via the m6A-dependent regulation of unfolded protein response., PMID:37208522
m6A-enriched lncRNA LINC00839 promotes tumor progression by enhancing TAF15-mediated transcription of amine oxidase AOC1 in nasopharyngeal carcinoma., PMID:37257820
VIRMA facilitates intrahepatic cholangiocarcinoma progression through epigenetic augmentation of TMED2 and PARD3B mRNA stabilization., PMID:37391589
A novel m6A/m5C/m1A score signature to evaluate prognosis and its immunotherapy value in colon cancer patients., PMID:37421455
Correction: Overexpression of VIRMA confers vulnerability to breast cancers via the m6A-dependent regulation of unfolded protein response., PMID:37450040
The yeast RNA methylation complex consists of conserved yet reconfigured components with m6A-dependent and independent roles., PMID:37490041
HNRNPC promotes collagen fiber alignment and immune evasion in breast cancer via activation of the VIRMA-mediated TFAP2A/DDR1 axis., PMID:37528369
Pan-cancer analysis and experimental validation revealed the m6A methyltransferase KIAA1429 as a potential biomarker for diagnosis, prognosis, and immunotherapy., PMID:37606975
KIAA1429/VIRMA promotes breast cancer progression by m6 A-dependent cytosolic HAS2 stabilization., PMID:37705505
VIRMA Facilitates Triple-Negative Breast Cancer Progression via Increasing m6A-Dependent KIF15 Expression., PMID:37811616
KIAA1429 Promotes Nasopharyngeal Carcinoma Progression by Mediating m6A Modification of PTGS2., PMID:37830191
KIAA1429 protects hepatocellular carcinoma cells from ferroptotic cell death with a m6 A-dependent posttranscriptional modification of SLC7A11., PMID:37830241
lncRNA POU6F2-AS1 Regulated by KIAA1429 Contributes to Colorectal Cancer Progression in an m6A Modification Manner., PMID:38103097
KIAA1429 facilitates metastasis via m6A-YTHDC1-dependent RND3 down-regulation in hepatocellular carcinoma cells., PMID:38224863
NME6 as a potential biomarker and therapeutic target involved in immune infiltration for lung adenocarcinoma., PMID:38517815
Inhibin A contributes to the tumorigenesis of oral squamous cell carcinoma by KIAA1429-mediated m6A modification., PMID:38531807
Asynchronous microexon splicing of LSD1 and PHF21A during neurodevelopment., PMID:38562691
VIRMA promotes the progression of head and neck squamous cell carcinoma by regulating UBR5 mRNA and m6A levels., PMID:38577917
Glycolysis and tumor progression promoted by the m6A writer VIRMA via m6A-dependent upregulation of STRA6 in pancreatic ductal adenocarcinoma., PMID:38604311
Hirschsprung's disease: m6A methylase VIRMA suppresses cell migration and proliferation by regulating GSK3β., PMID:38658662
KIAA1429 regulates lung adenocarcinoma proliferation and metastasis through the PI3K/AKT pathway by modulating ARHGAP30 expression., PMID:38717936
Role and mechanism of KIAA1429 in regulating cellular ferroptosis and radioresistance in colorectal cancer., PMID:38843497
KIAA1429 Induces m6A Modification of LINC01106 to Enhance the Malignancy of Lung Adenocarcinoma Cells via the JAK/STAT3 Pathway., PMID:38848293
KIAA1429 promotes gastric cancer progression by destabilizing RASD1 mRNA in an m6A-YTHDF2-dependent manner., PMID:38902717
KIAA1429 increases FOXM1 expression through YTHDF1-mediated m6A modification to promote aerobic glycolysis and tumorigenesis in multiple myeloma., PMID:39060874
METTL5 enhances the mRNA stability of TPRKB through m6A modification to facilitate the aggressive phenotypes of hepatocellular carcinoma cell., PMID:39182664
Small HBV surface antigen drives regorafenib resistance in HCC via KIAA1429-dependent m6A modification of CCR9., PMID:39206838
Silencing of KIAA1429, a N6-methyladenine methyltransferase, inhibits the progression of colon adenocarcinoma via blocking the hypoxia-inducible factor 1 signalling pathway., PMID:39215765
Structures and mechanisms of the RNA m 6A writer., PMID:39238441
Downregulation of the m6A reader YTHDC2 upregulates exosome content in lung adenocarcinoma via inhibiting IFIT and OAS family members., PMID:39303913
Neuronal splicing of the unmethylated histone H3K4 reader, PHF21A, prevents excessive synaptogenesis., PMID:39395799
The three YTHDF paralogs and VIRMA are strong cross-histotype tumor driver candidates among m6A core genes., PMID:39411658
N6-Methyladenosine Methyltransferase Component KIAA1429 Is a Potential Target of Cancer Therapy., PMID:39456252
Eosinophil extracellular traps drive T follicular helper cell differentiation via VIRMA-dependent MAF stabilization in bullous pemphigoid., PMID:39490750
The methyltransferase KIAA1429 potentiates cervical cancer tumorigenesis via modulating LARP1 mRNA m6A modification and stability., PMID:39558874
Alcohol-induced C/EBP β-driven VIRMA decreases oxidative stress and promotes pancreatic ductal adenocarcinoma growth and metastasis via the m6A/YTHDF2/SLC43A2 pathway., PMID:39900725
VIRMA-Mediated the m6A Methylation of SCD Facilitates Wilms' Tumor Progression via AMPK Pathway., PMID:40040483
m6A transferase KIAA1429 mediates the upregulation of LncRNA LINC00968 promoting the progression of gastric cancer cells., PMID:40069867
m6A RNA methylation dynamics during in vitro maturation of cumulus-oocyte complexes derived from adult or prepubertal sheep., PMID:40097858
VIRMA promotes NSCLC progression by modifying ADAR m6A and increasing the activity of the TGF-β signaling pathway., PMID:40254620
For research use only. Not for human or drug use.
